The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia
Ventilator-associated pneumonia (VAP) is an important cause of morbidity and mortality in ventilated critically ill patients specially in intensive care unit (ICU). It is associated with an increased duration of mechanical ventilation, high death rates and increased healthcare costs in the development country.
Although VAP is preventable and many practices have been demonstrated to reduce the incidence of this disease, the morbidity is still so high. VAP is hard to cure and the mortality is about to 40% which was reported in China in 2004. If the bacteria of multidrug-resistance(MDR) is isolated, the mortality can increase to 70%. So much more methods should be needed in treating VAP in addition to using antibiotics.
Ulinastatin is a serine protease inhibitor with a molecular weight of 67,000 found in healthy human urine. It is used worldwide for patients with inflammatory disorders, including disseminated intravascular coagulation(DIC),shock, and pancreatitis . Furthermore, ulinastatin administration can help reduce sepsis, prevent multiple organ dysfunction, and modulate immune functions.
Actually, three studies have showed that ulinastatin treatment is associated with reduced the levels of inflammatory factors in blood serum in patients with acute respiratory distress syndrome(ARDS).Though analyses of serum inflammatory factors such as tumor necrosis factor (TNF)-α and interleukin (IL)-6 have been used to determine the degree of systemic inflammation under various clinical conditions, they can not reflect the degrees of lung infection directly.
Basing on the results of previous studies, meta analyses and system reviews, the investigators hypothesized that the anti-inflammatory function of ulinaststin may also decrease the levels of inflammatory factors in bronchoalveolar lavage(BAL) fluid in Patients with VAP.
In addition there is no prospective study to investigate the role of ulinastatin in BAL. The investigator hopes that this study can approve the relationship between ulinastatin and inflammatory factors in BAL. And it can improve the processes,outcomes and costs of critical care as well.
Ventilator-associated Bacterial Pneumonia
Mechanical Ventilation Complication
Drug: Ulinaststin for injection
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
|Official Title:||The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia|
- Levels of inflammatory factors in bronchoalveolar lavage fluid and blood serum. [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]The variety of tumor necrosis factor-α(TNF-α),interleukin-10(IL-10),interleukin-18(IL-18) and interferon-γ(INF-γ) in bronchoalveolar lavage fluid and blood serum are observed.
- All cause mortality. [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Ventilation free days. [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Antibiotic free days. [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Percentage of MDR pathogenic bacteria. [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
We will find whether the bacteria of multidrug-resistance can be isolated from the bronchoalveolar lavage fluid culture.
We will count the number of methicillin-resistant staphylococcus aureus(MRSA),extended-spectrum beta-lactamase(ESBLs) or vancomycin-resistant enterococcus(VRE) isolated from bronchoalveolar lavage fluid culture.
- Oxygenation index [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]Oxygenation index = Fio2/PaO2(mmHg)
- Adverse effects [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]The adverse effects from using ulinastatin. Irritability,nausea,vomit,diarrhoea or the aspartate transaminaseere and alanine transaminase are more than one time the upper normal limit were regarded as the adverse effects.
|Study Start Date:||January 2014|
|Estimated Study Completion Date:||June 2016|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
The normal dose of ulinastatin for injection group(NUTIG):
Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 100,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP.
|Drug: Ulinaststin for injection|
The high dose of ulinastatin for injection group(HUTIG):
Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 200,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP.
|Drug: Ulinaststin for injection|
Placebo Comparator: CG
The compare group(CG):
The group was given 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP.
This is a one-center, three-arm, randomized, single-blinded, controlled trial. When a patient was diagnosed VAP during mechanic ventilation in ICU,a sealed envelop will be opened which decide whether the patient is assigned to the normal dose ulinastatin group,the high dose ulinastatin group or the compare group.
VAP diagnosis and treatment accord with the "Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia:Diagnosis and treatment" which was published in 2008 by Canadian critical care trials group.
The aim of the present study is to determine the efficacy of ulinastatin for the treatment of ventilator-associated Pneumonia(VAP) and to investigate the effect to inflammatory factors in bronchoalveolar lavage fluid .
Please refer to this study by its ClinicalTrials.gov identifier: NCT01865266
|Contact: Yu YueTian, MDfirstname.lastname@example.org|
|Contact: Liu ChunYan, MDemail@example.com|
|Shanghai Minhang Central Hospital||Not yet recruiting|
|Shanghai, China, 201199|
|Contact: Yu YueTian, MD 13818227011 firstname.lastname@example.org|
|Contact: Liu ChunYan, MD 13917836226 email@example.com|
|Principal Investigator: Yu YueTian, MD|
|Sub-Investigator: Mao EnQiang, MD|